SUBSCRIBE
SUBSCRIBE

Phase 2

Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Amgen’s Leukemia Drug Blinatumomab Gets FDA Priority Review
October 10, 2014
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Chimerix, Inc. Says Brincidofovir Improved Survival In Study Spurred By Boy
October 8, 2014
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Sanofi (France), Regeneron Pharmaceuticals, Inc.'s Dupilumab Successful In Phase 2 Study
September 30, 2014
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
TONIX Pharmaceuticals, Inc.'s Pain Drug Fails Phase 2b Study
September 29, 2014
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Flexion Therapeutics Reports FDA Clinical Hold For Phase 2b Trial Of Osteoarthritis Drug
September 18, 2014
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Gilead Sciences, Inc.'s Experimental Drug Simtuzumab Fails Mid-Stage Study
September 17, 2014
 · 
2 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Drug Development
Oxygen Biotherapeutics, Inc. Shares Gyrate After Halting Mid-Stage Brain Injury Trial
September 11, 2014
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
AstraZeneca PLC’s Phase 2 Lung Drug Data Gives Mixed Messages
September 8, 2014
 · 
2 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Drug Development
AstraZeneca PLC Pops On Possibility Of Another Pfizer Bid; Start Of New Cancer Trial
August 29, 2014
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Auxilium Pharmaceuticals Drug Found Effective Against Cellulite In Phase 2 Study
August 21, 2014
 · 
2 min read
Load More
PRESS RELEASES
Press Releases
Actio Biosciences Announces Initiation of KYRON Phase 1b/2 Trial of ABS-1230 for the Treatment of KCNT1-Related Epilepsy and Acceptance into FDA’s Rare Disease Evidence Principles Process
May 8, 2026
 · 
5 min read
Press Releases
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 8, 2026
 · 
13 min read
Press Releases
InnoCare Announces Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Sjögren’s Syndrome in China
May 8, 2026
 · 
3 min read
Press Releases
Vaxart Provides Business Update and Reports First Quarter 2026 Financial Results
May 8, 2026
 · 
12 min read
Press Releases
Beacon Therapeutics Announces Positive 12-Month Safety and Efficacy Update from Phase 2 DAWN Trial of laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) at ARVO 2026 Annual Meeting
May 8, 2026
 · 
6 min read
Press Releases
BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease
May 8, 2026
 · 
8 min read
Press Releases
Ukko Announces First Participant Dosed in Phase 1/2a Clinical Study Evaluating UKK-0018 for Peanut Allergy Treatment
May 7, 2026
 · 
3 min read
Press Releases
enGene Announces Updated Interim Results From LEGEND Pivotal Cohort
May 7, 2026
 · 
12 min read
Press Releases
Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA
May 7, 2026
 · 
8 min read
Press Releases
AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential
May 7, 2026
 · 
6 min read
Press Releases
Cardiol Therapeutics’ Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association
May 7, 2026
 · 
7 min read
Press Releases
Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study
May 7, 2026
 · 
5 min read
Press Releases
Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study
May 7, 2026
 · 
15 min read
Press Releases
PHERGain and PHERGain-2 advance therapeutic de-escalation in early HER2-positive breast cancer in selected patients
May 7, 2026
 · 
5 min read
Press Releases
Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
May 7, 2026
 · 
18 min read
Press Releases
Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer
May 7, 2026
 · 
7 min read
Press Releases
Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026
May 7, 2026
 · 
1 min read
Press Releases
Bioxodes presents positive final Phase 2a intracerebral hemorrhage results at ESOC affirming breakthrough potential of BIOX-101
May 6, 2026
 · 
5 min read
Press Releases
Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
May 6, 2026
 · 
10 min read
Press Releases
Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 6, 2026
 · 
14 min read
Load More